Just received this note in response to our June cover story. Dr. Guillory, Professor Emeritus at the University of Iowa's School of Pharmacy, says that industry has helped to create the shortage of Ph.D.-level life scientists in product development. Most colleges are focusing on biological sciences in order to obtain NIH funding, and top schools like Purdue, Iowa, Maryland and Minnesota are receiving little industry funding.
Would any of you have any thoughts on this subject?
..."It is interesting to hear pharmaceutical industry ceo's complainabout the lack of well-trained scientists in the area ofpharmaceutical product development. They should look in the mirrorto see who is to blame for this situation. Most colleges of pharmacyhave abandoned research and even course work in that area becausefaculty can obtain NIH funding only in the biological sciences.Consequently, new faculty hires continue to churn out carbon copiesof themselves, biological scientists, who proceed from one post-docto another. The few colleges that have at least modest programs inproduct development, Iowa, Purdue, Maryland, and Minnesota, receivevery little support from the industry. Sure, they get short-termcontracts from industry to solve specific problems, but they don'tget the kind of long term support that Deans value. To Deans, NIHfunding is the sine qua non, and NIH support is simply not availablefor fundamental work in the area of pharmaceutical productdevelopment. Unless that situation changes, and soon, even the fewschools with good programs will see them dwindle as older facultyretire and are replaced by biological scientists. Already, industryis hiring engineers and chemists to do the formulation work peoplewith backgrounds in pharmaceutics did in the past..."
J. Keith Guillory, Professor Emeritus, The University of Iowa, College of Pharmacy
Latest from Home
Latest from Home